	US 12,290,537 B2
	Methods and compositions for controlling or reducing pests
Marc Pagès Bosch, Amer (ES); Primitivo Caballero Murillo, Pamplona (ES); Marta Sitjà I Arnau, Amer (ES); David Martínez Durán, Saragossa (ES); and Javier Lucientes Curdi, Saragossa (ES)
Assigned to HIPRA SCIENTIFIC, S.L.U., Amer (ES); and UNIVERSIDAD PÚBLICA DE NAVARRA, Pamplona (ES)
Appl. No. 17/630,450
Filed by HIPRA SCIENTIFIC, S.L.U., Amer (ES); and UNIVERSIDAD PÚBLICA DE NAVARRA, Pamplona (ES)
PCT Filed Jul. 27, 2020, PCT No. PCT/EP2020/071144 § 371(c)(1), (2) Date Jan. 26, 2022, PCT Pub. No. WO2021/018841, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 19382646 (EP), filed on Jul. 26, 2019.
Prior Publication US 2022/0249577 A1, Aug. 11, 2022
Int. Cl. A61K 35/74 (2015.01); A01N 63/23 (2020.01); A01P 7/02 (2006.01); A61K 35/06 (2006.01); A61K 38/16 (2006.01); A61P 33/14 (2006.01)

CPC A61K 35/74 (2013.01) [A01N 63/23 (2020.01); A01P 7/02 (2021.08); A61K 35/06 (2013.01); A61K 38/164 (2013.01); A61P 33/14 (2018.01); A61K 2300/00 (2013.01)]

21 Claims

1. A pharmaceutical or biocide composition suitable for controlling or reducing mite infestations, comprising as an active ingredient a bacterial isolate of at least one strain of Bacillus thuringiensis (B. thuringiensis), wherein the bacterial isolate comprises an effective amount of viable spores of at least said one strain of B. thuringiensis; and wherein:

(a) the at least one strain of B. thuringiensis is a strain that produces less than 1.7 mg/ml of B. thuringiensis' non-spore proteins for every 3.1×10⁹viable spores per ml; and

(b) the pharmaceutical or biocide composition is in a pharmaceutical form selected from the group consisting of: dust, powder, granular formulation, microencapsulated formulation, lotion, ointment, gel, cream, paste, suspension, liquid concentrate, solution and emulsion.